Celltrion announced it has structurally eliminated tariff risks by securing US production facilities and stockpiling two years' supply, ensuring uninterrupted sales despite potential 25% US tariffs.
#YonhapInfomax #Celltrion #USTariffs #BranchburgFacility #ShareholderLetter #PharmaceuticalSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=102146

SK Biopharmaceuticals reports Q1 operating profit of 25.7 billion won, up 149% year-on-year but below market expectations, driven by U.S. sales growth of cenobamate despite temporary factors affecting revenue.
#YonhapInfomax #SKBiopharmaceuticals #Q1Earnings #OperatingProfit #Cenobamate #PharmaceuticalSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62447

SK Biopharm forecasts 230% increase in Q1 operating profit, driven by strong Xcopri sales despite absence of milestone payments, as company navigates potential U.S. tariff challenges
#YonhapInfomax #SKBiopharm #Xcopri #OperatingProfit #Q1Earnings #PharmaceuticalSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62393